NewsBenzingaUBS maintient sa recommandation neutre sur 10x Genomics et abaisse son objectif de cours à 61 $ UBS maintient sa recommandation neutre sur 10x Genomics et abaisse son objectif de cours à 61 $ Benzinga 2026.11.06 23:14 (GMT+0) Open on Benzinga Other news UBS Maintains Neutral on Liberty Media, Raises Price Target to $1116 UBS Maintains Neutral on Tripadvisor, Lowers Price Target to $9 Here’s How Much You Would Have Made Owning Roivant Sciences Stock In The Last 5 Years UBS Maintains Neutral on 10x Genomics, Lowers Price Target to $61 UBS Maintains Neutral on Veeva Systems, Raises Price Target to $325 UBS Upgrades Jinko Holdings to Buy, Lowers Price Target to $17
